Home | Welcome to Contract Pharma   
Last Updated Friday, October 31 2014
Print

Financial Report: Pfizer



Published January 29, 2013
Pfizer

4Q Revenues: $15.1 billion (-7%)

4Q Earnings: $6.3 billion (earnings were $1.4 billion in 4Q11)

YTD Revenues: $59.0 billion (-10%)

YTD Earnings: $14.6 billion (+46%)

Comments: U.S. revenues were $5.8 billion in the quarter, down 9% primarily due to the loss of exclusivity of Lipitor (-79% to $584 million) in November 2011 and Geodon in March 2012. International revenues were $9.3 billion, down 5% due to the losses for Lipitor in Europe in 2Q12 and the unfavorable impact of foreign exchange. Lyrica sales in the quarter were up 13% to $1.1 billion. Prevnar/Prevenar sales were up 19% to $993 million. Celebrex sales were up 12% to $750 million. Viagra sales were up 6% to $553 million. Zyvox sales were up 10% to $349 million. Enbrel sales were up 3% to $957 million. Primary care revenues were down 29% to $3.8 billion. Specialty Care revenues were down 4% to $3.7 billion. Established product sales were up 3% to $2.4 billion. Animal health sales were up 6% to $1.2 billion. Consumer Healthcare sales were up 16% to $936 million. Earnings in the quarter were favorably impacted by the sale of the Nutrition business.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On